Immatics NV
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.08
- Today's High:
- $12.685
- Open Price:
- $12.68
- 52W Low:
- $5.9
- 52W High:
- $13.14
- Prev. Close:
- $12.44
- Volume:
- 266620
Company Statistics
- Market Cap.:
- $984.07 million
- Book Value:
- 2.61
- Revenue TTM:
- $79.72 million
- Operating Margin TTM:
- -81.5%
- Gross Profit TTM:
- $172.83 million
- Profit Margin:
- -85.17%
- Return on Assets TTM:
- -12.29%
- Return on Equity TTM:
- -42.96%
Company Profile
Immatics NV had its IPO on 2020-07-02 under the ticker symbol IMTX.
The company operates in the Healthcare sector and Biotechnology industry. Immatics NV has a staff strength of 210 employees.
Stock update
Shares of Immatics NV opened at $12.68 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $12.08 - $12.69, and closed at $12.38.
This is a -0.48% slip from the previous day's closing price.
A total volume of 266,620 shares were traded at the close of the day’s session.
In the last one week, shares of Immatics NV have increased by +1.14%.
Immatics NV's Key Ratios
Immatics NV has a market cap of $984.07 million, indicating a price to book ratio of 6.1801 and a price to sales ratio of 4.7026.
In the last 12-months Immatics NV’s revenue was $79.72 million with a gross profit of $172.83 million and an EBITDA of $-61604000. The EBITDA ratio measures Immatics NV's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Immatics NV’s operating margin was -81.5% while its return on assets stood at -12.29% with a return of equity of -42.96%.
In Q2, Immatics NV’s quarterly earnings growth was a positive 0% while revenue growth was a negative 90.5%.
Immatics NV’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.23 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immatics NV’s profitability.
Immatics NV stock is trading at a EV to sales ratio of 2.8327 and a EV to EBITDA ratio of 9.9217. Its price to sales ratio in the trailing 12-months stood at 4.7026.
Immatics NV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $410.19 million
- Total Liabilities
- $124.31 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $10.83 million
- Dividend Payout Ratio
- 0%
Immatics NV ended 2024 with $410.19 million in total assets and $0 in total liabilities. Its intangible assets were valued at $410.19 million while shareholder equity stood at $218.21 million.
Immatics NV ended 2024 with $0 in deferred long-term liabilities, $124.31 million in other current liabilities, 804000.00 in common stock, $-544656000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $130.41 million and cash and short-term investments were $347.63 million. The company’s total short-term debt was $2,737,000 while long-term debt stood at $0.
Immatics NV’s total current assets stands at $364.63 million while long-term investments were $0 and short-term investments were $217.22 million. Its net receivables were $1.94 million compared to accounts payable of $5.47 million and inventory worth $9.55 million.
In 2024, Immatics NV's operating cash flow was $0 while its capital expenditure stood at $10.83 million.
Comparatively, Immatics NV paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $12.38
- 52-Week High
- $13.14
- 52-Week Low
- $5.9
- Analyst Target Price
- $18.24
Immatics NV stock is currently trading at $12.38 per share. It touched a 52-week high of $13.14 and a 52-week low of $13.14. Analysts tracking the stock have a 12-month average target price of $18.24.
Its 50-day moving average was $11.99 and 200-day moving average was $9.7 The short ratio stood at 15.54 indicating a short percent outstanding of 0%.
Around 2522.1% of the company’s stock are held by insiders while 4871.1% are held by institutions.
Frequently Asked Questions About Immatics NV
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.